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Dr Kalra’s commentary was intended to be a
preliminary, personal response to the DEVOTE
trial results as reported to the press. We apolo-
gise if it was not made sufficiently clear in the
article that the results of the DEVOTE trial
remain to be published in full, and have not yet
therefore undergone scientific review.
In addition, Table 1 should include all the
four arms of the ORIGIN trial: insulin
glargine ? omega-3 polyunsaturated fatty acids;
insulin glargine ? placebo; standard care ?
omega-3 polyunsaturated fatty acids; and pla-
cebo comparator: standard care ? placebo.
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